Lan Chem Laboratories plans to commercialize its current pipeline products directly in the UK via its own commercial organization targeting anesthesiologists and oncologists.
Outside the UK, the Company intends to commercialize Barhemsys® and APD403 via licensing and/or distribution agreements with selected pharmaceutical partners. Lan Chem Laboratories currently holds global rights to both products.
The Company will continue to assess further hospital opportunities to utilize its UK sales and marketing infrastructure, including in-licensing or acquiring complementary product candidates, as it did with Byfavo®, which it in-licensed from Cosmo Pharmaceuticals in January 2020.
To discuss opportunities, please contact busdev@lanchemlabs.com.